A general strategy is described for the amplified expression, purification and characterization in Escherichia coli of multidrug efflux proteins from Staphylococcus auteus, Bacillus subtilis, Methanococcus janaschii and E . coli. They all catalyse drug/H+ antiport of substrates such as quinolones and ethidium and exemplify a family of putatively 12-helix membrane proteins. The gene for each protein was cloned downstream of the tac promoter in plasmid pTTQl8 ; an oligonucleotide encoding six histidine residues was added, in frame, to the C-terminus to facilitate purification. Growth conditions were optimized in 1-25-litre cultures of E. coli host strains to amplify the expression of each protein ; the retention of activity was confirmed by assays of antibiotic resistance in vivo and/or assays of energized transport activity in vitro with synthetic substrates. Proteins were solubilized in dodecylmaltoside and purified to more than 90 yo homogeneity with Ni2+-nitrilotriacetate-affinity column chromography, yielding 5-25 mg per 25 litres of original culture. All the transport proteins migrated anomalously in SDS/PAGE at apparent molecular masses below those predicted from the gene sequence; identity and integrity were therefore confirmed by Nterminal amino acid sequencing and Western blotting for the C-terminal hexahistidine tag. Examination of the secondary structure of detergent-solubilized proteins by CD or Fouriertransform infrared spectroscopy following purification indicated a high content of a-helix (more
Introduction
Extensive analyses of the genomes of both prokaryotic and eukaryotic organisms reveal that most membrane transport proteins fall into two classes (http://www-biology.ucsd.edu/ yo7Eipaulsen/ transport/index.html). One of these, the 'ATPbinding cassette ' (ABC) superfamily, uses ATP to energize the transport of substrates across the membrane ( Figure 1) ; the second, the multifacilitator superfamily (MFS), might operate by facilitated diffusion, symport or antiport ( Figure  1 ). The ABC superfamily and other ATP-linked transport systems are not further considered here (see [1,2] and Bhattacharjee, Zhou, Li, Gatti, Walmsley and Rosen, this issue, pp. 520-526).
In bacteria, individual MFS proteins can accomplish the active accumulation of nutrient by a cation-substrate symport mechanism or by the active efflux of compounds such as antibiotics, antibacterials or toxins by a cation-substrate antiport mechanism (Figure 1 ). Some MFS proteins catalyse the efflux of antibiotics and antibacterials from both pathogenic and non-pathogenic bacteria. These efflux proteins often bind a broad range of substrates of various chemical natures, 'multidrugs', in contrast with the high degree of specificity characteristic of many transport proteins and enzymes in general. This broad specificity might account for their effectiveness in conferring on some bacteria their resistance to antibiotics ; its molecular origin in the structural features of the proteins is discussed by VazquezLaslop, Zheleznova, Markham, Brennan and Neyfakh (this issue, compare [3] ).
MFS proteins are thought to be single polypeptides comprising 12-14 transmembrane ahelices. This conclusion is usually based on an analysis of the hydropathic profile of the amino acid sequence of each protein predicted from its DNA sequence. In a few cases the prediction is reinforced by genetic, immunochemical or other types of topological experiments; in one case only, the Na+/H+ antiporter of Escherichia coli, is there structural information that confirms the 12-helix composition from electron diffraction analyses of two-dimensional protein crystals [4, 5] . This paucity of information on the actual structures of membrane transport proteins is due partly to their hydrophobicity, which means they can be solubilized and studied only in the presence of detergent.
In addition they are usually expressed at low levels, less than 0.1 yo of cell protein, which makes them difficult to purify in the milligram amounts needed for crystallization and structural determination. These practical difficulties can be exacerbated by the probable flexibility of the proteins themselves, which is invoked to account for their ability to bind substrate in, or on one side of, the membrane, and effect its translocation. In our laboratory a general strategy has been devised for the amplified expression, purification and characterization of bacterial membrane transport proteins in E. coli [ 6 ] . So far it has been successful for 18 prokaryote transport proteins, including the multidrug efflux proteins Bmr and Blt from Bacillus subtilis, NorA from Staphylococcus aureus, Mj 1506 ORF from Methanococcus janaschii, and Bcr from E . coli. In this article some general studies on the purification and properties of these efflux proteins are described, using the B.
subtilis Bmr efflux protein as the working example.
Amplified expression
Plasmid pTTQ18 [7] contains a tac promoter upstream of a multicloning site in the DNA 
Energization of sugar transport in 15 coli
The large oval represents the cytoplasmic membrane ofthe micro-organism. A transmembrane electrochemical gradient of protons is generated by respiration or ATP hydrolysis, depicted on the left. This can be utilized by the proton-nutrient symport or proton/drug antiport systems shown along the top. Some nutrients can be accumulated by an alternative mechanism involving ATP, a binding protein, and two or three other proteins shown along the bottom, with other ATP-dependent primary transport systems for efflux of toxins. A phosphotransferase mechanism involving phosphoenolpyruvate and two orthree proteins for sugar accumulation is shown on the upper right and facilitated transport (uniport) of glycerol on the lower right 
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encoding the LacZa peptide. There is also a laciq gene to overexpress Lac1 repressor protein and bla gene to confer ampicillin resistance (see [6] for details). T h e gene for each of the five proteins has been ligated downstream of the tac promoter; an oligonucleotide encoding six histidine residues and, usually, an epitope tag is added, in frame, to the C-terminus (amino acid sequence -RGSHH-HHHH). T h e N-terminal amino acid sequence might be slightly modified by a few amino acids from the a-peptide of the LacZ protein, which is in the multicloning site, but this does not prevent expression. Growth conditions are optimized in 1-25-litre cultures of E. coli host strains, testing both minimal and complex media to maximize the expression of each protein [6] . T h e concentration of isopropyl P-D-thiogalactoside (IPTG) required is tested between 0.1 and 1.0 m M ; the period of growth before induction is varied to obtain as many bacteria as possible commensurate with optimal proteisn expression, because growth is often diminished or abolished after induction. Similarly, the period of exposure to I P T G (2- Bmr can lyse after only a few hours. In many cases a 25-litre fermenter can conveniently be used without compromising expression, but for some proteins the level of expression is always higher in batch cultures of 500-800 ml in 2-litre baffled flasks.
Four of the efflux proteins studied so far are expressed in E. coli but are derived from other organisms. Retention of their activity in the heterologous host can be confirmed by measurements of resistance to an antibiotic in vivo by using filter discs containing for example 1Opg of norfloxacin, in which the zone of inhibition is compared between IPTG-induced and uninduced lawns of the host strain containing the plasmid derived from pTTQ18 by insertion of the gene of interest. In addition, inside-out membrane vesicles derived from the induced organism can be used for assays of energized transport activity in vitro by using synthetic substrates whose fluorescence is changed when they are transported out of the membrane ( Figure 2) [8].
24 h) is investigated to promote maximum expression and to avoid cell lysis : cells expressing
Purification of efflux proteins
Detailed procedures are described elsewhere [6] ; A number of detergents should be tested at concentrations spanning their critical micelle concentration to solubilize the efflux protein. We routinely use dodecyl-P-0-maltoside, N,Ndimethyldodecylamine-N-oxide (' LDAO '), Triton X-100 and Triton X-114. The detergenttreated samples are centrifuged at 108000-12OOOOg for 1 h to separate soluble and insoluble material ; the position of the overexpressed efflux protein is determined by SDS/PAGE of Coomassie-Blue-stained samples. Stabilizing additives such as glycerol and/or salt are also used.
A general observation is that dodecylmaltoside in the range 0.5-1.5 yo (w/v) 
Properties of the efflux proteins
In SDS/PAGE all the transport proteins migrate anomolously at apparent molecular masses below those predicted from the gene sequence, for example in the range 28-33 kDa when their predicted masses are 43-47 kDa. It is therefore important to confirm their identity and integrity by sequencing the N-terminal amino acids and by Western blotting for the C-terminal epitope tag. After quite extensive pretreatment procedures [9], matrix-assisted laser desorption ionization MS of the purified protein can be used to provide an indication of purity and to confirm the true molecular mass. Our pilot studies indicate that the Qtof electrospray ionization mass spectrometer can be particularly useful for determining both accurate molecular masses and confirming identity by the sequencing of partial proteolytic digests of the efflux protein.
The examination of solubilized proteins by C D or Fourier-transform infrared spectroscopy during purification indicates a high content of ahelix, which is tenaciously retained. Each of these methods has some drawbacks when an absolute value of the content of secondary structure is sought; however, they are very useful for monitoring the retention of structure during purification and crystallization trials. In addition, for some proteins the spectra are altered on the binding of ligands, indicating that substrate binding is retained; these changes form the bases of activity assays. Ideally, transport activity of the purified protein should be examined in reconstituted proteoliposomes. However, reincorporation of the efflux protein into liposomes is not always accomplished, perhaps because of aggregation of the protein, and transport assays are not always easy to implement without the additional incorporation of a proton-translocating respiratory chain or ATPase; additionally, for efflux proteins many substrates are lipophilic. The improvement of such procedures is an important goal.
Reconstitution of some of the proteins into membranes to form ordered two-dimensional arrays is more successful. Such arrays of purified Bmr(His), protein with lipid mixtures have been obtained that diffract electrons; molecules have been detected at a low resolution (1 5-20 A). These are different from the tubular arrays of Nha obtained for higher-resolution analyses [5, 6] .
The formation of three-dimensional crystals of Bmr(His), is being attempted, without obtaining crystals that diffract X-rays so far. Proteins have been prepared fused to green fluorescent protein (GFP) or maltose-binding protein (MBP) to provide a hydrophilic partner and potentially to aid these crystallization trials. Although the overexpression of the G F P fusion protein is often preserved, detergent solubilization and purification of the Bmr-GFP-(His), chimaera has proved to be of too low a yield and purity for structural analyses. However, the MBPBmr(His), fusion can be purified satisfactorily, although its biological activities have yet to be confirmed.
Conclusions
Efflux proteins such as Bmr or NorA can be purified as His-tagged fusion proteins ; physical measurements indicate that they retain the integrity of the amino acid sequence and of secondary and tertiary structure. Crystallization in two-dimensional arrays to use electron diffraction for structure determination is in its initial stages; however, three-dimensional crystals, of either the essentially native protein or chimaeras with ' crystallizable ' adducts, have not yet yielded diffracting material. Trials with added tightly binding ligands or with mutants that are hopefully 'locked' into an inflexible form are continuing.
The ultimate aim of this reserch is to use the overexpressed protein to isolate novel inhibitors of efflux systems, which might have therapeutic value. Such compounds might be found from random searches of combinatorial libraries, or, eventually, by rational design once the threedimensional nature of the ligand-binding site has been established. In a recent newspaper article [lo] the following was asserted: 'In the 1960s the surgeon-general of the United States announced that infectious disease was conquered.. . . Even as the surgeon-general spoke, many of (the bacteria) had already built little pumps that squirted out the antibiotic.. .faster than it could get in. ' The extent to which efflux systems contribute to resistance probably varies between organisms but the isolation of these proteins and elucidation of the properties might be critical for the development of important future antibacterials. example of BmrR demonstrates that a protein can bind multiple compounds with micromolar affinities by using only electrostatic and hydrophobic interactions. Its ligand specificity can be broadened by the flexibility of the binding site. It therefore seems that the commonly expressed fascination with the broad specificity of multidrug transporters is misdirected and originates from an almost exclusive familiarity with the more sophisticated processes of specific molecular recognition that predominate among existing proteins.
Multidrug transporters
All living cells express multidrug-efflux transporters. These membrane proteins actively extrude structurally dissimilar organic chemicals, thus protecting cells from their toxic effects. The first such transporter, mammalian P-glycoprotein, was discovered in the early 1970s. So far, owing to the efforts of many research groups, the list of multidrug transporters has grown to at least 100 and includes transporters of mammalian cells, lower eukaryotes, archaebacteria and both Grampositive and Gram-negative eubacteria [1] [2] [3] [4] .
Because many anti-tumour, anti-bacterial and anti-fungal agents used in clinics are substrates of multidrug transporters, these proteins create serious obstacles for the chemotherapy of cancer and infectious diseases and are therefore of immense clinical importance. However, it is not the clinical importance alone that makes the phenom-
